AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00980824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Referral to NHS services appropriate to patient's needs
Study NCT04113941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuronox
Description: intradetrusor injection
Study NCT04113941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intradetrusor injection
Study NCT02955303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECH: Tablet Enhancement of Cognition and Health
Description: cognitive training using touchscreen tablet gaming applications
Study NCT04569175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Flair sequence
Description: Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
Study NCT03682068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)
Study NCT03682068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous infusion)
Study NCT03682068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin + Gemcitabine
Description: Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Study NCT03682068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin + Gemcitabine
Description: Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Study NCT03682068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Gemcitabine
Description: Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Study NCT03682068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin + Gemcitabine
Description: Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
Study NCT03193047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempedoic acid 180mg
Description: Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
Study NCT03193047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy
Study NCT03193047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Monthly PCSK9i (evolocumab) background therapy
Study NCT03193047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: evolocumab
Description: Monthly PCSK9i (evolocumab) background therapy
Study NCT02871609 — intervention group
Intervention type: OTHER
Intervention: Stent examination, urinary analysis, USSQ questionnaire
Study NCT01999439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis with Dysphagia
Description: An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.~Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
Study NCT01999439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis with Dysphagia
Description: Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
Study NCT01429844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
Study NCT01429844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
Study NCT02221648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomization to receive either the study drug or the placebo group.
Study NCT02221648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA Treatment
Description: Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
Study NCT05739604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample analysis
Description: The concentrations of AAs and related compounds were determined by liquid chromatography/mass spectrometry (LC/MS)
Study NCT00371956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raloxifene
Description: 60mg/day
Study NCT00371956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tab 1 daily
Study NCT03569397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patients will be administered music therapy during the operation.
Study NCT03701880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
Study NCT03701880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
Study NCT03701880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol is beta-blocker
Study NCT03701880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol is beta-blocker
Study NCT04211597 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No scar prevention or treatment.
Study NCT03639246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is experimental drug
Study NCT04211597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silicone gel
Description: Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)
Study NCT04211597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silicone gel
Description: Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)
Study NCT04211597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microencapsulated polysaccharide and oligopeptide-1(Me-EGF) 40 mcg & 5 mcg
Description: 4ml (40 mcg) of Me-EGF spray will be given by the operating physician prior to wound closure, followed by daily application of 5 mcg until day +5 after delivery. Starting from day +14, participants will receive FDA approved Silicone gel to be applied to the Cesarean wound twice a day for two months. Participants also receive routine post-partum care as usual.
Study NCT01261117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ibuprofen
Description: oral or iv ibuprofen in 10, 5 and 5 mg/kg/day with 24 hr intervals
Study NCT03639246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Pac)
Description: Paclitaxel is active comparator
Study NCT03639246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (Pac)
Description: Paclitaxel is active comparator
Study NCT03639246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: PLD is active comparator
Study NCT03639246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: PLD is active comparator
Study NCT03639246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT02364388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imagio IUS
Description: Imagio diagnostic gray-scale ultrasound
Study NCT02364388 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Imagio IUS
Description: Imagio diagnostic gray-scale ultrasound
Study NCT02364388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imagio OA/US
Description: Diagnostic opto-acoustic +gray-scale ultrasound
Study NCT02364388 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Imagio OA/US
Description: Diagnostic opto-acoustic +gray-scale ultrasound
Study NCT02373150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Study NCT02373150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03063736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entolimod
Description: The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
Study NCT03063736 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Td Vaccine
Description: The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
Study NCT03063736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Td Vaccine
Description: The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
Study NCT04453761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurobion
Description: Intravenous Thiamine 2 mg/kg in Neurobion injection
Study NCT04453761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous NaCl0.9%
Study NCT01285869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional intervention
Description: The patient will be cited 2 months after hospital discharge for a geriatric evaluation carried out by a geriatric nurse and an internist with geriatric training. The duration of the first visit is 45-60 minutes. The visit consists of: 1. Assessment of the pneumonia resolution, co-morbidities, aspiration risk, risk of multiresistant infections, and the immunization, functional and cognitive status. 2. An individualized intervention plan. The patient and family or caregiver will receive an educational intervention, a written report with the planned intervention and an educational leaflet. Those patients who require further assessment or follow up of the intervention will receive 1 or 2 more visits and all the patients will be cited one year after the first visit.
Study NCT02303600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
Study NCT02303600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
Study NCT03973853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality driving stimulation program
Description: This group will benefit of 14 one hour sessions, using the driving simulator. The program is based on a progressive training, focused on the remediation of the cognitive functions specific to driving. The tool and the type of training aim to help transfer the abilities to daily life.
Study NCT03973853 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TAU
Description: This group will carry on their usual treatment during the whole length of the study. Patients will be randomized into the 2 groups. This TAU group will be the control group and will help assess the effectiveness of the stimulation program. The stimulation sessions will be proposed to the TAU group at the end of study.
Study NCT03221166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
Study NCT02738359 — intervention group
Intervention type: PROCEDURE
Intervention: optical colonoscopy
Description: optical colonoscopy
Study NCT03221166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab is a chimeric monoclonal antibody against TNF alpha
Study NCT01644084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Description: Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
Study NCT01644084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl starch 130/0.4
Description: Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
Study NCT03434444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin in solution, ranging from 10 -12M to 10 -5M
Study NCT03434444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol in solution, 10-6M
Study NCT04168970 — intervention group
Intervention type: PROCEDURE
Intervention: PSGB
Description: Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.
Study NCT02334280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In SHAPE
Description: In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
Study NCT03261687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water based exercise
Study NCT03261687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: land based exercise
Study NCT03261687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advice
Description: general advice given to all subjects
Study NCT02738359 — intervention group
Intervention type: PROCEDURE
Intervention: colon capsule endoscopy
Description: colon capsule endoscopy
Study NCT04243746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Subjects practise TRF (2-3 meals) as an adjunct to the QQH healthy plate diet. Subjects of the intervention group can eat during the pre-determined 8-12 hours eating window, but they are only allowed to drink water and calorie-free drinks for the remaining 12-16 hours. Subjects are allowed to decide the time of their first and the last meal of the day as long as they eat within the 8-12 hour window period. However, skipping breakfast and having late dinner are discouraged.
Study NCT02738359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fecal immunological test (FIT)
Description: fecal immunological test (FIT)
Study NCT01598805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic alerts
Description: An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
Study NCT04243746 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Subjects practice the QQH healthy plate diet as per guidelines set by the Health Ministry the guidelines.QQH refers to a normal food plate (23cm in diameter), divided into a quarter of rice (carbohydrates), a quarter of meat (protein) and a half plate of vegetables and fruits. Additionally, no calories specification is required and snacks are discouraged.
Study NCT02879786 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Posturographic tests
Study NCT02879786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posturographic tests
Study NCT02879786 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire of motion sickness susceptibility
Study NCT02879786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire of motion sickness susceptibility
Study NCT01162863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
Study NCT02899065 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Description: Procalcitonin is a blood test used to differentiate between viral and bacterial infections. This test is expected to aid in determining the best course of treatment for patients enrolled into this arm.
Study NCT02899065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-Led Education
Description: Pharmacists will interpret the results of the Roche Cobas Liat Flu/RSV assay and procalcitonin test (if available) and provide the treating physician with recommendations for antibiotic therapy based on these results.
Study NCT01162863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taken orally for 28 days
Study NCT01162863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartpill wireless motility capsule
Description: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
Study NCT01162863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smartpill wireless motility capsule
Description: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
Study NCT00631267 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Manual Manipulation
Description: The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
Study NCT00631267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Finger Trap Traction
Description: Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
Study NCT02849444 — intervention group
Intervention type: OTHER
Intervention: Anti-myeloma treatment at physician discretion
Description: non Interventional Study
Study NCT05142007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
Study NCT05142007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction
Description: A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
Study NCT04230122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3478006 - IV
Description: Administered IV
Study NCT04230122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3478006 - SC
Description: Administered SC